Valneva (VALN) secured marketing authorization in the UK for its Ixchiq vaccine for chikungunya, a mosquito-borne viral disease.
The vaccine, manufactured at the company's leading production site in Livingston, Scotland, got the approval from the Medicines and Healthcare products Regulatory Agency,
The single-dose vaccine is for active immunization for the prevention of disease caused by the chikungunya virus in people 18 years of age and older, Valneva said Wednesday in a statement.
The vaccine is approved in the US, Europe and Canada in adults, and Valneva expects to get marketing approval in Brazil in Q1.
Valneva submitted label extension applications in the US, Europe and Canada to possibly extend the use of Ixchiq to adolescents aged 12 to 17 years and plans to submit a label extension application in the UK.
The company's shares rose 14% in recent Wednesday trading.
Price: 6.43, Change: +0.82, Percent Change: +14.69
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。